Regulation & News
503A vs 503B Compounding Pharmacies, Explained
A plain-English guide to the two federal compounding pathways, who they cover, what quality rules apply, and why the difference matters for peptides.
Regulation & News
FDA actions, compounding law (503A/503B) and advisory committees, explained with primary sources.
Regulation & News
BPC-157 and the FDA: What the July 2026 Advisory Committee Vote Actually Means
An FDA advisory panel voted 8–6 to recommend BPC-157 for the 503A bulks list. Here is what that vote did, what it did not do, and what the evidence shows.
Regulation & News
FDA's Interim Peptide Compounding Policy: What We Know So Far (Updated)
HHS and FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House for review. Here is what is confirmed, what is reported, and what is still unknown.